Skip to Main Content

Advertisement

Skip Nav Destination

Emerging Technologies and Data Science

Studies, methods, and large datasets that employ computational biology, high-throughput techniques, imaging, physical sciences, or engineering to investigate cancer biology

Latest in Emerging Technologies and Data Science
Victoria Hoskin, Abdi Ghaffari et al.
The main cause of cancer-associated death is the spread of cancer cells to distant organs. Despite its success in the primary tumor setting, modern chemotherapeutic strategies are rendered ineffective at treating metastatic disease, largely due to the development of resistance. The adaptor protein ezrin has been shown to ...
Laxmi Silwal-Pandit, Stina M. Stålberg et al.
Pancreatic cancer remains a disease with unmet clinical needs and inadequate diagnostic, prognostic and predictive biomarkers. In-depth characterization of the disease proteome is limited. This study thus aims to define and describe protein networks underlying pancreatic cancer and identify protein centric subtypes with ...
Galaxia M Rodriguez, Kristianne J.C. Galpin et al.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative need for new treatments. Immunotherapy has had marked success in some cancer types; however, clinical trials studying the efficacy of immune checkpoint inhibitors for the treatment of EOC benefited less than 15% of patients. Given ...
Karoline Pudelko, Angela Wieland et al.
The acquisition of cell invasiveness is the key transition from benign melanocyte hyperplasia to aggressive melanoma. Recent work has provided an intriguing new link between the presence of supernumerary centrosomes and increased cell invasion. Moreover, supernumerary centrosomes were shown to drive non–cell-autonomous ...
Husain Yar Khan, Misako Nagasaka et al.
The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door to targeting KRAS G12C selectively. These agents have shown promise in preclinical tumor models and clinical trials. FDA has recently granted approval to sotorasib for KRAS ...
Wubin Qian, Xiaobo Chen et al.
Tumor biology is determined not only by immortal cancer cells but also by the tumor microenvironment consisting of noncancerous cells and extracellular matrix, together they dictate the pathogenesis and response to treatments. Tumor purity is the proportion of cancer cells in a tumor. It is a fundamental property of ...
Mary Jo Fackler, Suzana Tulac et al.
Current molecular liquid biopsy assays to detect recurrence or monitor response to treatment require sophisticated technology, highly trained personnel, and a turnaround time of weeks. We describe the development and technical validation of an automated Liquid Biopsy for Breast Cancer Methylation (LBx-BCM) prototype, a ...
Margaret L. Axelrod, Yu Wang et al.
Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast cancer. We identified ...
Qiujin Shen, Yahui Feng et al.
Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the ...
Alina Castell, Qinzi Yan et al.
Deregulated expression of MYC family oncogenes occurs frequently in human cancer and is often associated with aggressive disease and poor prognosis. While MYC is a highly warranted target, it has been considered “undruggable,” and no specific anti-MYC drugs are available in the clinic. We recently identified molecules ...
Close Modal

or Create an Account

Close Modal
Close Modal